sorry, we can't preview this file
Table_1_In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma.DOCX
Multiple myeloma is a life-threatening hematological malignancy, which is rarely curable by conventional therapies. Immunotherapy, using tumor antigen-specific, cytotoxic T-lymphocytes, may represent an alternative or additional treatment for multiple myeloma. In this study, we used hybrid cell lines, generated by fusion of an EBV B-lymphoblastoid cell line (B-LCL) and myeloma cells, to stimulate in vitro peripheral blood lymphocytes (PBLs) from patients with multiple myeloma. We investigated induction of antigen-specific, cytotoxic T-lymphocytes to the well-defined tumor associated antigens (TAAs) hTERT, MUC1, MAGE-C1 and CS1, which have been shown to be expressed in a high proportion of cases of multiple myeloma. HLA-A2-peptide pentamer staining, interferon-γ and perforin ELISpot assays, as well as cytotoxicity assays were used. Following several rounds of in vitro stimulation, the hybrid cell lines induced antigen-specific, cytotoxic T-lymphocytes to four candidate TAAs in PBLs from HLA-A2+ multiple myeloma patients, using known HLA-A2 restricted peptide epitopes of the TAAs. In contrast, the HLA-A2+ myeloma cell line U266 failed to induce antigen-specific, cytotoxic T-lymphocytes in vitro. Our data indicate that B-LCL/myeloma hybrid cell lines induce antigen-specific, cytotoxic T-lymphocytes in PBLs isolated from multiple myeloma patients in vitro and may represent a novel strategy for use in adoptive immunotherapy of multiple myeloma.
History
References
- https://doi.org//10.4161/hv.24235
- https://doi.org//10.3390/ijms17060828
- https://doi.org//10.1084/jem.162.1.45
- https://doi.org//10.1084/jem.167.6.1811
- https://doi.org//10.1046/j.1365-2567.1999.00912.x
- https://doi.org//10.1111/j.1399-0039.2006.00623.x
- https://doi.org//10.1111/j.1600-0609.2006.00769.x
- https://doi.org//10.1002/eji.1830120804
- https://doi.org//10.1016/j.vaccine.2012.08.032
- https://doi.org//10.1016/j.imbio.2011.12.001
- https://doi.org//10.1126/science.2326647
- https://doi.org//10.5041/RMMJ.10179
- https://doi.org//10.1002/phar.1871
- https://doi.org//10.1111/j.1365-2141.2007.06705.x
- https://doi.org//10.1182/blood-2012-05-429415
- https://doi.org//10.1073/pnas.202491499
- https://doi.org//10.1182/blood-2002-09-2828
- https://doi.org//10.1158/1078-0432.CCR-13-0282
- https://doi.org//10.1111/j.1365-2141.2004.04929.x
- https://doi.org//10.1038/nm1310
- https://doi.org//10.1182/blood-2010-08-299396
- https://doi.org//10.1097/CJI.0b013e3181bed253
- https://doi.org//10.1053/j.seminhematol.2009.02.001
- https://doi.org//10.1038/sj.bmt.1705393
- https://doi.org//10.1038/sj.bmt.1705742
- https://doi.org//10.1016/j.exphem.2009.03.008
- https://doi.org//10.1080/14712598.2017.1375095
- https://doi.org//10.1111/j.1365-2141.2006.06331.x
- https://doi.org//10.1111/j.1365-2141.2006.06484.x
- https://doi.org//10.1182/blood-2007-07-099366
- https://doi.org//10.1155/2012/257695
- https://doi.org//10.1182/blood-2007-08-107292
- https://doi.org//10.1182/blood-2011-07-369686
- https://doi.org//10.1182/blood-2008-10-183772
- https://doi.org//10.1073/pnas.070560797
- https://doi.org//10.1007/s00011-013-0632-1
- https://doi.org//10.1158/1078-0432.CCR-10-1340
- https://doi.org//10.1002/ijc.25613
- https://doi.org//10.1016/0306-9877(95)90203-1
- https://doi.org//10.1016/0167-5699(96)80614-1
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity